Drug Trial Radar · NCT07920172
Clinical Trial of Recombinant Herpes Zoster Vaccine (ZFA01 Adjuvant, CHO Cells)
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Nov 10, 2026
Primary completion
May 23, 2029
Study completion May 23, 2029
Sponsor
- Lead sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A seamless Phase I/II trial evaluating the immunogenicity and safety of a recombinant herpes zoster ZFA01 adjuvanted vaccine (CHO cell) in healthy adults aged ≥40 years. Phase I (n=100): randomized, blinded, placebo-controlled, age/dose escalation across 4 cohorts. Phase II (n=400): randomized, open-label, active-controlled, with 1:1 or 1:1:1 allocation to two experimental groups and a positive control group across three age strata.
Conditions
- Herpes Zoster
Interventions
Low-dose adjuvanted recombinant zoster vaccineBiological
0.5 mL per dose, containing 50 μg varicella-zoster virus glycoprotein E (gE) plus 375 μg adjuvant, intramuscular administration, 2 doses at Day 0 and Day 30.
High-dose adjuvanted recombinant zoster vaccine (0 and 30 days schedule)Biological
0.5 mL per dose, containing 50 μg varicella-zoster virus glycoprotein E (gE) plus 750 μg adjuvant, intramuscular administration, 2 doses at Day 0 and Day 30.
High-dose adjuvanted recombinant zoster vaccine (0 and 60 days schedule)Biological
0.5 mL per dose, containing 50 μg varicella-zoster virus glycoprotein E (gE) plus 750 μg adjuvant, intramuscular administration, 2 doses at Day 0 and Day 60.
Low-dose adjuvant placeboBiological
0.5 mL per dose, containing 375 μg adjuvant only, no varicella-zoster virus glycoprotein E (gE), intramuscular administration, 2 doses at Day 0 and Day 30.
High-dose adjuvant placeboBiological
0.5 mL per dose, containing 750 μg adjuvant only, no varicella-zoster virus glycoprotein E (gE), intramuscular administration, 2 doses at Day 0 and Day 30.
Zoster Vaccine Recombinant, AdjuvantedBiological
0.5 mL per dose, containing 50 μg varicella-zoster virus glycoprotein E (gE), adjuvanted with AS01B, intramuscular administration, 2 doses at Day 0 and Day 60.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Endpoints(1):Occurrence of all AEsTime frame: within 30 days after each dose of vaccination
- Safety Endpoints(2):Occurrence of all SAEsTime frame: from the first dose up to 12 months after completion of the full vaccination series
- Safety Endpoints(3):Occurrence of all pIMDsTime frame: from the first dose up to 12 months after completion of the full vaccination series
- Immunogenicity Endpoints (1): GMTs of VZV gE antibody and VZV antibodyTime frame: at pre-first dose, 30 days after completion of full vaccination series, and 6 and 12 months after completion of full vaccination series
- Immunogenicity Endpoints (2): GMIs of VZV gE antibody and VZV antibodyTime frame: at 30 days, 6 months, and 12 months after completion of full vaccination series
- Immunogenicity Endpoints (3): Seropositivity rates of VZV gE antibody and VZV antibodyTime frame: at pre-first dose, 30 days after completion of full vaccination series, and 6 and 12 months after completion of full vaccination series
- Immunogenicity Endpoints (4): Seroconversion rates of VZV gE antibody and VZV antibody.Time frame: at 30 days after completion of full vaccination series
- Immunogenicity Endpoints (5): Detection frequency of CD4²⁺ T cells secreting at least two gE-specific cytokines (IFN-γ, IL-2, TNF-α, CD40L, IL-17A)Time frame: at pre-first dose, 30 days after completion of full vaccination series, and 6 and 12 months after completion of full vaccination series
- Percentage of Participants With Clinically Significant Serum Chemistry Laboratory AbnormalitiesTime frame: Pre-vaccination (Baseline), Day 4 after the first dose
- Percentage of Participants With Clinically Significant Hematology Laboratory AbnormalitiesTime frame: Pre-vaccination (Baseline), Day 4 after the first dose
- Percentage of Participants With Clinically Significant Urinalysis Laboratory AbnormalitiesTime frame: Pre-vaccination (Baseline), Day 4 after the first dose
- Percentage of Participants With Clinically Significant Coagulation Laboratory AbnormalitiesTime frame: Pre-vaccination (Baseline), Day 4 after the first dose
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Guangxi Zhuang Autonomous Region People's Hospital
Guangxi, Nanning, China · Recruiting
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention
Guangxi, Nanning, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.